ATE225799T1 - Rezeptor modulierendes mitteln und entsprechendes verfahren - Google Patents

Rezeptor modulierendes mitteln und entsprechendes verfahren

Info

Publication number
ATE225799T1
ATE225799T1 AT95916284T AT95916284T ATE225799T1 AT E225799 T1 ATE225799 T1 AT E225799T1 AT 95916284 T AT95916284 T AT 95916284T AT 95916284 T AT95916284 T AT 95916284T AT E225799 T1 ATE225799 T1 AT E225799T1
Authority
AT
Austria
Prior art keywords
receptor modulating
corresponding method
modulating agent
receptor
vitamin
Prior art date
Application number
AT95916284T
Other languages
English (en)
Inventor
A Charles Morgan
D Scott Wilbur
Pradip M Pathare
Original Assignee
Receptagen Corp
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/406,192 external-priority patent/US5739287A/en
Priority claimed from US08/406,191 external-priority patent/US5840880A/en
Priority claimed from US08/406,194 external-priority patent/US5869465A/en
Application filed by Receptagen Corp, Univ Washington filed Critical Receptagen Corp
Application granted granted Critical
Publication of ATE225799T1 publication Critical patent/ATE225799T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT95916284T 1994-04-08 1995-04-07 Rezeptor modulierendes mitteln und entsprechendes verfahren ATE225799T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22483194A 1994-04-08 1994-04-08
US08/406,192 US5739287A (en) 1994-04-08 1995-03-16 Biotinylated cobalamins
US08/406,191 US5840880A (en) 1994-04-08 1995-03-16 Receptor modulating agents
US08/406,194 US5869465A (en) 1994-04-08 1995-03-16 Methods of receptor modulation and uses therefor
PCT/US1995/004404 WO1995027723A1 (en) 1994-04-08 1995-04-07 Receptor modulating agents and methods relating thereto

Publications (1)

Publication Number Publication Date
ATE225799T1 true ATE225799T1 (de) 2002-10-15

Family

ID=27499380

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95916284T ATE225799T1 (de) 1994-04-08 1995-04-07 Rezeptor modulierendes mitteln und entsprechendes verfahren

Country Status (9)

Country Link
US (2) US5840712A (de)
EP (1) EP0754189B1 (de)
JP (1) JPH10502334A (de)
KR (1) KR100361075B1 (de)
AT (1) ATE225799T1 (de)
AU (1) AU2283595A (de)
CA (1) CA2187346C (de)
DE (1) DE69528523T2 (de)
WO (1) WO1995027723A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ323127A (en) * 1995-10-19 2001-03-30 Receptagen Corp Vitamin B12 receptor modulating agents and methods related thereto
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
EP1007533B1 (de) 1996-08-27 2005-06-22 University Of Utah Research Foundation Biokonjugate und verabreichung von bioaktiven substanzen
AU2003204343B2 (en) * 1998-06-12 2007-03-15 Access Pharmaceuticals Australia Pty Limited Vitamin B12 derivatives and methods for their preparation
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals
AU8366398A (en) * 1998-07-07 2000-01-24 Department Of Radiation Oncology University Of Washington Trifunctional reagent for conjugation to a biomolecule
WO2000011479A1 (en) * 1998-08-20 2000-03-02 Axis-Shield Asa Assay method for cardiovascular disease
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
AUPQ071299A0 (en) * 1999-06-02 1999-06-24 Access Pharmaceuticals Australia Pty Limited Vitamin directed dual targeting therapy
CA2387767A1 (en) 1999-10-15 2001-04-26 Henricus P. C. Hogenkamp Cobalamin conjugates useful as imaging and therapeutic agents
EP1231942A1 (de) * 1999-10-15 2002-08-21 Mayo Foundation For Medical Education And Research Kobalamin-konjugate anwendbar wie bilderzeugungsmitteln und wie antikrebsmitteln
US7591995B2 (en) 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
CA2387503C (en) * 1999-10-26 2010-02-09 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
US6797521B2 (en) * 1999-10-26 2004-09-28 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
WO2001072458A1 (en) * 2000-03-27 2001-10-04 Zyomyx, Inc. Site-specific, covalent bioconjugation of proteins
DE60127970T2 (de) 2000-06-30 2007-12-20 Eli Lilly And Co., Indianapolis Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält
US20020151525A1 (en) * 2000-10-25 2002-10-17 Collins Douglas A. Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation
WO2002042427A2 (en) * 2000-10-25 2002-05-30 Surromed, Inc. Mass tags for quantitative analysis
JP2004535371A (ja) * 2001-03-16 2004-11-25 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション 蛍光コバラミンおよびその使用
PL373511A1 (en) * 2001-05-15 2005-09-05 Faulk Pharmaceuticals, Inc. Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use
US6752986B2 (en) * 2001-05-24 2004-06-22 The Cleveland Clinic Foundation Composition and methods for affecting metallocorrinoid uptake
WO2003026674A1 (en) * 2001-09-28 2003-04-03 Mayo Foundation For Medical Education And Research Coadministration of transport protein with conjugated cobalamin to deliver agents
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
CA2516453A1 (en) * 2003-02-20 2004-09-02 The Cleveland Clinic Foundation Composition and methods for inhibiting cell survival
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
KR101126138B1 (ko) 2003-12-22 2012-04-12 솔리다고 아게 비정상적 세포 증식의 진단 및 치료에 유용한 코발아민유도체
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
CN101222853B (zh) * 2005-05-17 2012-07-18 卡吉尔公司 粒状卵磷脂、粒状溶血卵磷脂、它们的生产方法和包含它们的组合物
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
EP2010226B1 (de) * 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalaminrezeptor-Polypeptide, -Nukleinsäuren und -Modulatoren sowie entsprechende Verfahren zur Verwendung für die Modulation von Zellwachstum und die Behandlung von Krebs und Cobalaminmangel
WO2008098930A1 (en) * 2007-02-14 2008-08-21 Biocompatibes Uk Limited Derivatisation of biological molecules
CN101715342A (zh) * 2007-03-19 2010-05-26 因弗拉布洛克制药公司 钴胺素紫杉烷生物结合物
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
US20120231069A1 (en) 2011-03-08 2012-09-13 Access Pharmaceuticals, Inc. Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167556A (en) * 1977-06-02 1979-09-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Determination of transcobalamins
EP0069450B1 (de) * 1981-06-22 1985-04-10 TECHNICON INSTRUMENTS CORPORATION (a New York corporation) Markierte Vitamin-B12-Derivate, ihre Herstellung und Verwendung
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US5241070A (en) * 1988-09-26 1993-08-31 Ciba Corning Diagnostics Corp. Nucleophilic polysubstituted aryl acridinium esters and uses thereof
CA1339491C (en) * 1988-09-26 1997-10-07 Say-Jong Law Nucleophilic polysubstituted aryl acridinium ester and uses thereof
US5196510A (en) * 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
DE3900648A1 (de) * 1989-01-11 1990-07-12 Boehringer Mannheim Gmbh Neue cobalamin-saeurehydrazide und davon abgeleitete cobalamin-konjugate
EP0425680A4 (en) * 1989-02-28 1992-07-08 Teijin Limited New vitamin b 12? derivative, production thereof, and application thereof
US5310656A (en) * 1989-06-26 1994-05-10 Tritech Partners Vitamin B12 assay
US5294536A (en) * 1992-04-23 1994-03-15 Pb Diagnostic Systems, Inc. Conjugates
ATE163679T1 (de) * 1992-05-08 1998-03-15 Receptagen Corp Anti-rezeptor antikörper gegen den vitamin b12/transcobalamin ii rezeptor
DE4239815A1 (de) * 1992-11-26 1994-06-01 Boehringer Mannheim Gmbh Verbesserte B¶1¶¶2¶-Konjugate
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5739287A (en) * 1994-04-08 1998-04-14 University Of Washington Biotinylated cobalamins
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins

Also Published As

Publication number Publication date
KR970702290A (ko) 1997-05-13
EP0754189B1 (de) 2002-10-09
CA2187346C (en) 2010-06-29
US5840712A (en) 1998-11-24
DE69528523T2 (de) 2003-06-12
US6083926A (en) 2000-07-04
EP0754189A1 (de) 1997-01-22
WO1995027723A1 (en) 1995-10-19
AU2283595A (en) 1995-10-30
DE69528523D1 (de) 2002-11-14
CA2187346A1 (en) 1995-10-19
JPH10502334A (ja) 1998-03-03
KR100361075B1 (ko) 2003-04-10

Similar Documents

Publication Publication Date Title
DE69528523D1 (de) Rezeptor modulierendes mitteln und entsprechendes verfahren
ES2190479T3 (es) Moduladores de rxr selectivos a dimeros y metodos para su uso.
ATE417931T1 (de) Für den il-13 rezeptor spezifische chimäre proteine und ihre verwendungen
DE69616873D1 (de) Überbrückungsvorrichtung für Gelenkprothese
NO994998L (no) Fusjonsproteiner
DE59610329D1 (de) Airblast-Zerstäuberdüse
FI842420A0 (fi) Immunotoxinkonjugater beroerande foerbaettringar.
AU4675499A (en) Novel therapeutic agents that modulate neurokinin receptors
BR9609738A (pt) Composições para aplicação de droga para estabilidade melhorada de esteróides
ATE192317T1 (de) Bremskniegelenk
FI980862A0 (fi) Kiraalisia metyylifenyylioksatsolidinoneja
DE69840415D1 (de) Haemasterlin analoge
NO974440D0 (no) Azatioprinsammensetninger for tykktarmsadministrering
ATE297904T1 (de) Halo-alkoxycarbonylverbindungen
BR9608328A (pt) Derivados de benzil piperidina como agentes farmacêuticos
PT749734E (pt) Protese total de articulacao do joelho
AU4425399A (en) Novel therapeutic agents that modulate 5-ht receptors
PY0101314A (es) Compuestos farmaceuticos
FR2767526B1 (fr) Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant
DE69622826D1 (de) Einheit zum Zuführen von Zigarettenschichten
NL1002801A1 (nl) Borstel geschikt voor aanbrenging op een veegmachine.
DE69612960D1 (de) Kühlbare verbindung zum verbinden von rohrteilstücken
KR970001356A (ko) 접합고리 피리딘을 함유한 벤즈이미다졸 유도체
ES2159087T3 (es) Oxindoles sustituidos con adamantilo como agentes farmaceuticos.
KR970004494U (ko) 용접 장치용 용접 팁

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties